The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

A controversial anti-obesity drug is set to become more widely available on the NHS. Orlistat, otherwise known as Xenical, has been prescribed free to some obese patients for the past two years.

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Tirzepatide is already being used as a treatment for type 2 diabetes and obesity, under the names 'Manjaro' for type 2 diabetes and 'Zepbound' for obesity. The FDA's approval of tirzepatide for ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly ... giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie ...

The FDA’s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA. “Too often, OSA is brushed off as ‘just ...

Eli Lilly's Zepbound drug holds potential to dominate ... “Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four ...